IDEAS home Printed from https://ideas.repec.org/f/pga966.html
   My authors  Follow this author

Martina Garau

Personal Details

First Name:Martina
Middle Name:
Last Name:Garau
Suffix:
RePEc Short-ID:pga966
[This author has chosen not to make the email address public]

Affiliation

Office of Health Economics

London, United Kingdom
http://www.ohe.org/
RePEc:edi:ohecouk (more details at EDIRC)

Research output

as
Jump to: Working papers Articles Books

Working papers

  1. Zhang, K. & Garau, M., 2020. "International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making," Consulting Reports 002271, Office of Health Economics.
  2. Cubi-Molla, P. & Errea, M. & Zhang, K. & Garau, M., 2020. "Are Cost-Effectiveness Thresholds fit for Purpose for Real-World Decision Making?," Consulting Reports 002247, Office of Health Economics.
  3. Sampson, C. & Garau, M., 2019. "How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy," Briefings 002146, Office of Health Economics.
  4. Zamora, B. & Cookson, G. & Garau, M., 2019. "Unrelieved Pain in Palliative Care in England," Consulting Reports 002197, Office of Health Economics.
  5. Berdud, M. & Garau, M. & Neri, M. & O'Neill, P. & Sampson, C. & Towse, A., 2018. "R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C," Research Papers 002040, Office of Health Economics.
  6. Neri, M. & Towse, A. & Garau, M., 2018. "Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward," Briefings 002084, Office of Health Economics.
  7. Towse, A. & Garau, M., 2018. "Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence," Consulting Reports 001978, Office of Health Economics.
  8. Hernandez-Villafuerte, K. & Garau, M. & Towse, T. & Garrison, L., 2017. "Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study," Consulting Reports 001781, Office of Health Economics.
  9. Zamora, B. & Maignen, F. & O'Neill, P. & Mestre-Ferrandiz, J. & Garau, M., 2017. "Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries," Consulting Reports 001818, Office of Health Economics.
  10. Hernandez-Villafuerte, K. & Garau, M. & Towse, A. & Garrison, L. & Grewal, S., 2017. "Policy Options for Formulary Development in Middle-income Countries," Consulting Reports 001784, Office of Health Economics.
  11. Cole, A. & Lundqvist, A. & Lorgelly, P. & Norrlid, H. & Karlsberg Schaffer, S. & Lewis, F. & Hernandez-Villafuerte, K. & Lindgren, P. & Garau, M. & Welin, K-O & Bianchi, S. & Althin, R. & O'Neill, P. , 2016. "Improving Efficiency and Resource Allocation in Future Cancer Care," Consulting Reports 001748, Office of Health Economics.
  12. Garau, M. & Marsden, G. & Devlin, N. & Amedeo Mazzanti, N. & Profico, A., 2016. "Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders' Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)," Research Papers 001773, Office of Health Economics.
  13. Rejon-Parrilla, J.C & Garau, M. & Sussex, J., 2014. "Obstructive Sleep Apnoea: Health Economics Report," Consulting Reports 001504, Office of Health Economics.
  14. Shah, K. & Sussex, J. & Hernandez-Villafuerte, K. & Garau, M. & Rotolo, D. & Hopkins, M.M & Grassano, N. & Crane, P. & Lang, F. & Hutton, J. & Pateman, C. & Mawer, A. & Farrell, C. & Sharp, T., 2014. "Exploring the Interdependencies of Research Funders in the UK," Research Papers 000519, Office of Health Economics.
  15. Sussex, J. & Rollet, P. & Garau, M. & Schmitt, C. & Kent, A. & Hutchings, A., 2013. "Multi-Criteria Decision Analysis to Value Orphan Medicines," Research Papers 000114, Office of Health Economics.
  16. Garau, M. & Shah, K. & Sharma, P. & Towse, A., 2013. "Exploring the link between health and wealth in decision making," Research Papers 000037, Office of Health Economics.
  17. Garau, M. & Towse, A. & Garrison, L. & Housman, L. & Ossa, D., 2012. "Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?," Research Papers 000160, Office of Health Economics.
  18. Garau, M. & Towse, A. & Danzon, P., 2011. "Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?," Occasional Papers 000191, Office of Health Economics.
  19. Garau, M. & Mordoh, A. & Sussex, J., 2011. "Exploring the Interdependency between Public and Charitable Medical Research," Consulting Reports 000187, Office of Health Economics.
  20. Garau, M. & Shah, K. & Mason, A.R & Wang, Q. & Towse, A. & Drummond, M.F, 2010. "Using QALYs in Cancer: Review of the Methodological Limitations," Research Papers 000211, Office of Health Economics.
  21. Mestre-Ferrandiz, J. & Garau, M. & O'Neill, P. & Sussex, J., 2010. "Assessment of the Impact of Orphan Medicinal Products on the European Economy and Society," Consulting Reports 000203, Office of Health Economics.
  22. Garau, M. & Mestre-Ferrandiz, J., 2009. "Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries," Briefings 000227, Office of Health Economics.
  23. Garau, M. & Shah, K. & Towse, A. & Wang, Q. & Drummond, M.F & Mason, A. R., 2009. "Assessment and Appraisal of Oncology Medicines: NICE's Approach and International HTA Experience," Consulting Reports 000234, Office of Health Economics.
  24. Garau, M. & Sussex, J., 2007. "Estimating Pharmaceutical Companies' Value to the Nation: Case Study of the British Pharma Group," Briefings 000245, Office of Health Economics.
  25. Gray, A. & Fenn, P. & Garau, M. & Pritchard, C. & Godber, E. & Towse, A., 2006. "Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions," Consulting Reports 000265, Office of Health Economics.

Articles

  1. Martina Garau & Grace Hampson & Nancy Devlin & Nicola Amedeo Mazzanti & Antonio Profico, 2018. "Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)," PharmacoEconomics - Open, Springer, vol. 2(2), pages 153-163, June.

Books

  1. Garau, M. & Mestre-Ferrandiz, J., 2007. "European Medicines Pricing and Reimbursement: Now and the Future," Monographs, Office of Health Economics, number 000263.

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Blog mentions

As found by EconAcademics.org, the blog aggregator for Economics research:
  1. Sampson, C. & Garau, M., 2019. "How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy," Briefings 002146, Office of Health Economics.

    Mentioned in:

    1. Chris Sampson’s journal round-up for 7th September 2020
      by Chris Sampson in The Academic Health Economists' Blog on 2020-09-07 11:00:07

Working papers

  1. Cubi-Molla, P. & Errea, M. & Zhang, K. & Garau, M., 2020. "Are Cost-Effectiveness Thresholds fit for Purpose for Real-World Decision Making?," Consulting Reports 002247, Office of Health Economics.

    Cited by:

    1. Javad Moradpour & Aidan Hollis, 2021. "The economic theory of cost‐effectiveness thresholds in health: Domestic and international implications," Health Economics, John Wiley & Sons, Ltd., vol. 30(5), pages 1139-1151, May.

  2. Berdud, M. & Garau, M. & Neri, M. & O'Neill, P. & Sampson, C. & Towse, A., 2018. "R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C," Research Papers 002040, Office of Health Economics.

    Cited by:

    1. Neri, M. & Towse, A. & Garau, M., 2018. "Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward," Briefings 002084, Office of Health Economics.
    2. Roediger, Alexander & Wilsdon, Tim & Haderi, Artes & Pendleton, Kathy & Azais, Boris, 2019. "Competition between on-patent medicines in Europe," Health Policy, Elsevier, vol. 123(7), pages 652-660.
    3. Doug Coyle & Isabelle Durand-Zaleski & Jasmine Farrington & Louis Garrison & Johann-Matthias Graf von der Schulenburg & Wolfgang Greiner & Louise Longworth & Aurélie Meunier & Anne-Sophie Moutié & Ste, 2020. "HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(9), pages 1421-1437, December.

  3. Neri, M. & Towse, A. & Garau, M., 2018. "Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward," Briefings 002084, Office of Health Economics.

    Cited by:

    1. Carlos Campillo-Artero & Jaume Puig-Junoy & José Luis Segú-Tolsa & Marta Trapero-Bertran, 2020. "Price Models for Multi-indication Drugs: A Systematic Review," Applied Health Economics and Health Policy, Springer, vol. 18(1), pages 47-56, February.
    2. Rosella Levaggi & Paolo Pertile, 2020. "Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition," Applied Health Economics and Health Policy, Springer, vol. 18(3), pages 357-362, June.

  4. Zamora, B. & Maignen, F. & O'Neill, P. & Mestre-Ferrandiz, J. & Garau, M., 2017. "Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries," Consulting Reports 001818, Office of Health Economics.

    Cited by:

    1. Alice Varnava & Robert Bracchi & Karen Samuels & Dyfrig A. Hughes & Philip A. Routledge, 2018. "New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes," PharmacoEconomics, Springer, vol. 36(5), pages 613-624, May.

  5. Hernandez-Villafuerte, K. & Garau, M. & Towse, A. & Garrison, L. & Grewal, S., 2017. "Policy Options for Formulary Development in Middle-income Countries," Consulting Reports 001784, Office of Health Economics.

    Cited by:

    1. Hernandez-Villafuerte, K. & Garau, M. & Towse, T. & Garrison, L., 2017. "Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study," Consulting Reports 001781, Office of Health Economics.

  6. Shah, K. & Sussex, J. & Hernandez-Villafuerte, K. & Garau, M. & Rotolo, D. & Hopkins, M.M & Grassano, N. & Crane, P. & Lang, F. & Hutton, J. & Pateman, C. & Mawer, A. & Farrell, C. & Sharp, T., 2014. "Exploring the Interdependencies of Research Funders in the UK," Research Papers 000519, Office of Health Economics.

    Cited by:

    1. Adèle Paul-Hus & Nadine Desrochers, 2019. "Acknowledgements are not just thank you notes: A qualitative analysis of acknowledgements content in scientific articles and reviews published in 2015," PLOS ONE, Public Library of Science, vol. 14(12), pages 1-13, December.
    2. Nicola Grassano & Daniele Rotolo & Joshua Hutton & Frédérique Lang & Michael M. Hopkins, 2017. "Funding Data from Publication Acknowledgments: Coverage, Uses, and Limitations," Journal of the Association for Information Science & Technology, Association for Information Science & Technology, vol. 68(4), pages 999-1017, April.

  7. Sussex, J. & Rollet, P. & Garau, M. & Schmitt, C. & Kent, A. & Hutchings, A., 2013. "Multi-Criteria Decision Analysis to Value Orphan Medicines," Research Papers 000114, Office of Health Economics.

    Cited by:

    1. Garau, M. & Marsden, G. & Devlin, N. & Amedeo Mazzanti, N. & Profico, A., 2016. "Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders' Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)," Research Papers 001773, Office of Health Economics.
    2. Aris Angelis & Mark Thursz & Vlad Ratziu & Alastair O’Brien & Lawrence Serfaty & Ali Canbay & Ingolf Schiefke & Joao Bana e Costa & Pascal Lecomte & Panos Kanavos, 2020. "Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis," Medical Decision Making, , vol. 40(6), pages 830-845, August.
    3. Monika Wagner & Hanane Khoury & Jacob Willet & Donna Rindress & Mireille Goetghebeur, 2016. "Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation," PharmacoEconomics, Springer, vol. 34(3), pages 285-301, March.
    4. Berdud, M. & Drummond, M.F & Towse, A., 2018. "Establishing a Reasonable Price for an Orphan Drug," Research Papers 002036, Office of Health Economics.
    5. Monika Wagner & Hanane Khoury & Jacob Willet & Donna Rindress & Mireille Goetghebeur, 2016. "Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation," PharmacoEconomics, Springer, vol. 34(3), pages 285-301, March.
    6. Michael Drummond & Adrian Towse, 2014. "Orphan drugs policies: a suitable case for treatment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(4), pages 335-340, May.
    7. Aris Angelis & Panos Kanavos, 2016. "Value-Based Assessment of New Medical Technologies: Towards a Robust Methodological Framework for the Application of Multiple Criteria Decision Analysis in the Context of Health Technology Assessment," PharmacoEconomics, Springer, vol. 34(5), pages 435-446, May.
    8. Kevin Marsh & J. Jaime Caro & Alaa Hamed & Erica Zaiser, 2017. "Amplifying Each Patient’s Voice: A Systematic Review of Multi-criteria Decision Analyses Involving Patients," Applied Health Economics and Health Policy, Springer, vol. 15(2), pages 155-162, April.
    9. Mike Paulden & Tania Stafinski & Devidas Menon & Christopher McCabe, 2015. "Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework," PharmacoEconomics, Springer, vol. 33(3), pages 255-269, March.
    10. Angelis, A. & Linch, M. & Montibeller, G. & Molina-Lopez, T. & Zawada, A. & Orzel, K. & Arickx, F. & Espin, J. & Kanavos, P., 2020. "Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework," Social Science & Medicine, Elsevier, vol. 246(C).
    11. William C. N. Dunlop & C. Daniel Mullins & Olaf Pirk & Ron Goeree & Maarten J. Postma & Ashley Enstone & Louise Heron, 2016. "BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles," PharmacoEconomics, Springer, vol. 34(10), pages 1051-1065, October.
    12. Carlos Campillo-Artero & Jaume Puig-Junoy & Anthony J. Culyer, 2018. "Does MCDA Trump CEA?," Applied Health Economics and Health Policy, Springer, vol. 16(2), pages 147-151, April.

  8. Garau, M. & Towse, A. & Garrison, L. & Housman, L. & Ossa, D., 2012. "Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?," Research Papers 000160, Office of Health Economics.

    Cited by:

    1. Rejon-Parrilla, J.C & Hernandez-Villafuerte, K. & Shah, K. & Mestre-Ferrandiz, J. & Garrison, L. & Towse, A., 2014. "The Expanding Value Footprint of Oncology Treatments," Consulting Reports 000050, Office of Health Economics.
    2. David J. Mott & Grace Hampson & Martin J. Llewelyn & Jorge Mestre-Ferrandiz & Michael M. Hopkins, 2020. "A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance," Applied Health Economics and Health Policy, Springer, vol. 18(1), pages 69-79, February.
    3. Gregory S. Zaric, 2016. "Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision Medicine," PharmacoEconomics, Springer, vol. 34(7), pages 635-644, July.
    4. James Buchanan & Sarah Wordsworth, 2015. "Welfarism Versus Extra-Welfarism: Can the Choice of Economic Evaluation Approach Impact on the Adoption Decisions Recommended by Economic Evaluation Studies?," PharmacoEconomics, Springer, vol. 33(6), pages 571-579, June.

  9. Garau, M. & Towse, A. & Danzon, P., 2011. "Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?," Occasional Papers 000191, Office of Health Economics.

    Cited by:

    1. Afschin Gandjour, 2013. "Reference Pricing and Price Negotiations for Innovative New Drugs," PharmacoEconomics, Springer, vol. 31(1), pages 11-14, January.
    2. Sabine Vogler, 2019. "Fair prices for medicines? Exploring competent authorities’ and public payers’ preferences on pharmaceutical policies," Empirica, Springer;Austrian Institute for Economic Research;Austrian Economic Association, vol. 46(3), pages 443-469, August.

  10. Garau, M. & Shah, K. & Mason, A.R & Wang, Q. & Towse, A. & Drummond, M.F, 2010. "Using QALYs in Cancer: Review of the Methodological Limitations," Research Papers 000211, Office of Health Economics.

    Cited by:

    1. David Feeny, 2013. "Standardization and Regulatory Guidelines May Inhibit Science and Reduce the Usefulness of Analyses Based on the Application of Preference-Based Measures for Policy Decisions," Medical Decision Making, , vol. 33(3), pages 316-319, April.
    2. Jose Luis Pinto Prades & Fernando Sanchez Martínez & Belen Corbacho, 2011. "Valuing qalys at the end of life," Working Papers 11.15, Universidad Pablo de Olavide, Department of Economics.
    3. Shah, Koonal K. & Tsuchiya, Aki & Wailoo, Allan J., 2015. "Valuing health at the end of life: A stated preference discrete choice experiment," Social Science & Medicine, Elsevier, vol. 124(C), pages 48-56.
    4. SeungJin Bae & SooOk Lee & Eun Bae & Sunmee Jang, 2013. "Korean Guidelines for Pharmacoeconomic Evaluation (Second and Updated Version)," PharmacoEconomics, Springer, vol. 31(4), pages 257-267, April.
    5. Aris Angelis & Panos Kanavos, 2016. "Value-Based Assessment of New Medical Technologies: Towards a Robust Methodological Framework for the Application of Multiple Criteria Decision Analysis in the Context of Health Technology Assessment," PharmacoEconomics, Springer, vol. 34(5), pages 435-446, May.
    6. Garau, M. & Towse, A. & Garrison, L. & Housman, L. & Ossa, D., 2012. "Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?," Research Papers 000160, Office of Health Economics.
    7. James D. Chambers & Teja Thorat & Colby L. Wilkinson & Mark Salem & Prasun Subedi & Sachin J. Kamal-Bahl & Peter J. Neumann, 2017. "Estimating Population Health Benefits Associated with Specialty and Traditional Drugs in the Year Following Product Approval," Applied Health Economics and Health Policy, Springer, vol. 15(2), pages 227-235, April.
    8. Angelis, Aris & Kanavos, Panos, 2016. "Value-based assessment of new medical technologies: towards a robust methodological framework for the application of multiple criteria decision analysis in the context of health technology assessment," LSE Research Online Documents on Economics 65148, London School of Economics and Political Science, LSE Library.
    9. Mathilda Bongers & Veerle Coupé & Elise Jansma & Egbert Smit & Carin Groot, 2012. "Cost Effectiveness of Treatment with New Agents in Advanced Non-Small-Cell Lung Cancer," PharmacoEconomics, Springer, vol. 30(1), pages 17-34, January.

  11. Garau, M. & Mestre-Ferrandiz, J., 2009. "Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries," Briefings 000227, Office of Health Economics.

    Cited by:

    1. Rejon-Parrilla, J.C & Hernandez-Villafuerte, K. & Shah, K. & Mestre-Ferrandiz, J. & Garrison, L. & Towse, A., 2014. "The Expanding Value Footprint of Oncology Treatments," Consulting Reports 000050, Office of Health Economics.
    2. Hanna, E. & Toumi, M. & Dussart, C. & Borissov, B. & Dabbous, O. & Badora, K. & Auquier, P., 2018. "Funding breakthrough therapies: A systematic review and recommendation," Health Policy, Elsevier, vol. 122(3), pages 217-229.
    3. Michael Drummond & Adrian Towse, 2014. "Orphan drugs policies: a suitable case for treatment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(4), pages 335-340, May.
    4. Nicholas Bagley & Benjamin Berger & Amitabh Chandra & Craig Garthwaite & Ariel D. Stern, 2018. "The Orphan Drug Act at 35: Observations and an Outlook for the Twenty-First Century," NBER Chapters, in: Innovation Policy and the Economy, Volume 19, pages 97-137, National Bureau of Economic Research, Inc.
    5. Todd Gammie & Christine Y Lu & Zaheer Ud-Din Babar, 2015. "Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries," PLOS ONE, Public Library of Science, vol. 10(10), pages 1-24, October.
    6. Sussex, J. & Rollet, P. & Garau, M. & Schmitt, C. & Kent, A. & Hutchings, A., 2013. "Multi-Criteria Decision Analysis to Value Orphan Medicines," Research Papers 000114, Office of Health Economics.
    7. Denis, Alain & Mergaert, Lut & Fostier, Christel & Cleemput, Irina & Simoens, Steven, 2010. "A comparative study of European rare disease and orphan drug markets," Health Policy, Elsevier, vol. 97(2-3), pages 173-179, October.

Articles

    Sorry, no citations of articles recorded.

Books

  1. Garau, M. & Mestre-Ferrandiz, J., 2007. "European Medicines Pricing and Reimbursement: Now and the Future," Monographs, Office of Health Economics, number 000263.

    Cited by:

    1. Garau, M. & Mestre-Ferrandiz, J., 2009. "Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries," Briefings 000227, Office of Health Economics.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 6 papers announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.
  1. NEP-HEA: Health Economics (4) 2018-05-21 2018-05-21 2019-03-25 2020-06-08
  2. NEP-COM: Industrial Competition (1) 2018-10-15
  3. NEP-INO: Innovation (1) 2018-10-15
  4. NEP-MKT: Marketing (1) 2018-05-21
  5. NEP-ORE: Operations Research (1) 2020-03-09
  6. NEP-TID: Technology & Industrial Dynamics (1) 2018-10-15

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Martina Garau should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.